June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Systematic review and meta-analysis on the efficacy of LipiFlow® device in the treatment of Meibomian Gland Dysfunction
Author Affiliations & Notes
  • Eddie Y Liu
    Ophthalmology, Western University, London, ON, Canada
    Schulich School of Medicine, London, ON, Canada
  • Monali Malvankar
    Ophthalmology, Western University, London, ON, Canada
    Epidemiology, Western University, London, ON, Canada
  • Sera Thomas
    Epidemiology, Western University, London, ON, Canada
  • John Costella
    Taylor Library, Western University, London, ON, Canada
  • Cindy M L Hutnik
    Ophthalmology, Western University, London, ON, Canada
    Pathology, Western University, London, ON, Canada
  • Footnotes
    Commercial Relationships Eddie Liu, None; Monali Malvankar, None; Sera Thomas, None; John Costella, None; Cindy Hutnik, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4433. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Eddie Y Liu, Monali Malvankar, Sera Thomas, John Costella, Cindy M L Hutnik; Systematic review and meta-analysis on the efficacy of LipiFlow® device in the treatment of Meibomian Gland Dysfunction. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4433.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine the effectiveness of LipiFlow® in the treatment of Meibomian gland dysfunction (MGD).

 
Methods
 

Published and unpublished scientific work from January 1, 2000 to July 15, 2014 were systematically reviewed using bibliographic databases (MEDLINE, EMBASE, BIOSIS Previews, CINAHL, HEED, ISI Web of Science and Cochrane Library) and grey literature by key words and search strategies. Potential studies were screened by two independent reviewers according to the following inclusion criteria: 1) research studies 2) human subjects older than 19 year of age with dry eyes and 3) treated with LipiFlow® or a similar thermal pulsation device. Downs and Black checklist was used to assess study quality. Data was extracted by 2 independent reviewers from 13 eligible articles. Standardized mean difference (SDM) was computed as the effect size. Effect sizes were calculated for meibomian gland excretion (MG) score, tear break-up time (TFBUT), SPEED and OSDI questionnaires.

 
Results
 

Up to 3 months after a single LipiFlow® treatment, significant improvement from baseline measures were seen in MG scores (SMD 1.64, 95% CI: 1.42, 1.85), TFBUT (SMD 0.62, 95% CI: 0.42, 0.83), SPEED (SMD -1.15, 95% CI: -1.36, -0.95) and OSDI (SMD -0.81, 95% CI: -1.01, -0.60). Single study data also showed the following significant improvement: up to 48 months after a single Lipiflow® treatment significant improvement was seen in MG score (SMD 2.68, 95% CI: 1.77, 3.59); 3 month following MeiboPatch® compress with massage treatment significant improvement was seen in MG score (SMD 0.63, 95% Cl: 0.02, -0.81), SPEED (SMD -1.02, 95% Cl: -1.01, 0.30) and OSDI (SMD - 0.75, 95% Cl: -1.37, -0.13); 3 month after warm compress with massage treatment significant improvement was seen in MG score (SMD 0.91, 95% Cl: 0.36, 1.46); and 2 weeks after iHeat® treatment significant improvement was seen in OSDI (SMD - 0.41, 95% Cl: -0.65, -0.18).

 
Conclusions
 

Lipiflow® is an effective treatment option of MGD. It improves objective and subjective measures of dry eye symptoms up to 3 months after a single Lipiflow treatment. Further studies are needed to confirm the effectiveness at and beyond 1 year after treatment.<br /> Ultimately, the cost-effectiveness of Lipiflow® treatment in the management of MGD will determine its clinical applicability.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×